Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | PPM1B | O75688 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.48 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PPP5C | P53041 | 1/20 | 0.48 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3187149 | 1.00 | KDM4E (0.48) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL18724559 | 1.00 | KDM4E (0.48) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL3187147 | 1.00 | KDM4E (0.48) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL10062651 | 1.00 | KDM4E (0.48) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL13483332 | 0.89 | KDM4E (0.46) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL13483328 | 0.89 | KDM4E (0.46) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL6746009 | 0.89 | KDM4E (0.46) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL6746008 | 0.89 | KDM4E (0.46) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL3190481 | 0.89 | KDM4E (0.46) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL3190490 | 0.89 | KDM4E (0.46) | KDM4EGMNNPPM1BLMNAPPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045418-B2 | Compounds, compositions and methods for treatment and prevention of Orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045418-B2 | Compounds, compositions and methods for treatment and prevention of Orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140316145-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES, INC., (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140316145-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES, INC., (US) | 2014-10-23 | — | — | US | disclosed |
| US-8802714-B2 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802714-B2 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8530509-B2 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530509-B2 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8124643-B2 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120020922-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-7737168-B2 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7687641-B2 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687641-B2 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20080103181-A9 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080004452-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004452-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070287735-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287735-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287735-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | KDM4E 3057/4885GMNN 2951/4885PPM1B 82/4885 |
| US-20080103181-A9 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | KDM4E 3219/4885GMNN 2832/4885PPM1B 107/4885 |
| US-20080004452-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | KDM4E 3057/4885GMNN 2951/4885PPM1B 82/4885 |
| US-20140316145-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | OTC, FAHD1, VAC14 | KDM4E 3277/4885GMNN 2721/4885PPM1B 85/4885 |
| US-20120020922-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | OTC, FAHD1, VAC14 | KDM4E 3277/4885GMNN 2721/4885PPM1B 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.